SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Outset Medical, Inc. (NASDAQ: OM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. What if I purchased Outset Medical securities? If you purchased securities and suffered ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Outset Medical, Inc. ("Outset" or the "Company") (NASDAQ: OM) on behalf of Outset stockholders. Our investigation concerns whether Outset has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or mi ...

LOS ANGELES, Aug. 9, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Outset released its second quarter 2024 financial results on August 7, 2024. The ...

Outset Medical (NASDAQ:OM) stock is taking a beating on Thursday after the medical technology company announced earnings results for the second quarter of the year. The Outset Medical earnings report starts with an adjusted EPS of -47 cents. That's worse than the -43 cents per share that Wall Street was expecting. That's despite it being better than the -69 cents per share from the same period of the year prior. On top of that, Outset Medical posted revenue of $27.39 million during the quarter. That's anoth ...

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.30%. A quarter ago, it was expected that this company would post a loss of $0.53 per share when it actually produced a loss of $0.57, delivering a surprise of -7.55%. Over the last four quarters, the company has sur ...

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Revenues are expected to be $31.19 million, down 13.5% from the year-ago quarter. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. The Zacks Earnings ESP compares the ...

Outset Medical, Inc. (OM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Most Powerful Force Impacting Stock Prices The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressiv ...

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.55%. A quarter ago, it was expected that this company would post a loss of $0.61 per share when it actually produced a loss of $0.59, delivering a surprise of 3.28%.Over the last four quarters, the company has surpas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39513 Outset Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-0514392 (State or other jurisdictio ...

Exhibit 99.1 Outset Medical Reports First Quarter 2024 Financial Results San Jose, CA – May 8, 2024 – Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024. "With our recent 510(k) clearance for TabloCart with Prefiltration, 12 th consecutive quarter of gross margin expansion and strong sales pipeline growth ...